Ignite Creation Date:
2024-05-06 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 12:47 PM
Study NCT ID:
NCT03561233
Status:
COMPLETED
Last Update Posted:
2018-06-21
First Post:
2018-06-07
Brief Title:
Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis
Sponsor:
Khon Kaen University
Organization:
Khon Kaen University
Study Overview
Official Title:
Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Proton pump inhibitor PPI twice daily dosing regimen-a standard dose therapy for gastroesophageal reflux disease GERD-is an effective therapy for uncomplicated GERD in systemic sclerosis SSc but there is no data of response rate of standard dose of PPI and predictors of PPI-partial response PPI-PR GERD in SScObjectives of the study were to determine the prevalence of omeprazole partial response GERD in SSc and to define the predictors of PPI-PR GERD in SSc Adult SSc patients having GERD were treated with omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks Severity of symptom-grading by visual analogue scale VAS and frequency of symptoms by frequency scale for symptoms of GERD FSSG were assessed at baseline and 4 weeks after treatment PPI-PR GERD was defined by less than 50 improvement in VAS of severity of symptom and acid reflux score by FSSG after treatment compare to baseline
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None